Daclizumab in treatment of multiple sclerosis patients

被引：19

作者：

Ali, E. N. ^{[1
]}

Healy, B. C. ^{[1
]}

Stazzone, L. A. ^{[1
]}

Brown, B. A. ^{[1
]}

Weiner, H. L. ^{[1
]}

Khoury, S. J. ^{[1
]}

机构：

[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Partners MS Ctr, Boston, MA 02115 USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2009年 / 15卷 / 02期

关键词：

all clinical trials; daclizumab; disease modifying therapies; multiple sclerosis; ANTIBODY; PSORIASIS;

D O I：

10.1177/1352458508097468

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background Daclizumab is a humanized monoclonal antibody (mAb) that blocks the interleukin-2 receptor alpha subunit (IL-2R-alpha chain; CD25) expressed on activated T cells leading to the inhibition of T-cell expansion, thus strongly reduces brain inflammation in patients with multiple sclerosis (MS). Another mechanism is significant expansion of CD56 (bright) natural killer (NK) cells that in turn inhibit T-cell survival. Objective At the Partners MS center, we have been using Daclizumab in an open-label fashion in patients who fail first line therapy or non-standard immunosuppressive treatment. Our aim was to assess its safety and tolerability in our patient population. Multiple Sclerosis 2009; 15: 272-274. http://msj.sagepub.com

引用

页码：272 / 274

页数：3

共 8 条

[1] Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β [J].

Bielekova, B ;

Richert, N ;

Howard, T ;

Blevins, G ;

Markovic-Plese, S ;

McCartin, J ;

Würfel, J ;

Ohayon, J ;

Waidmann, TA ;

McFarland, HF ;

Martin, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (23) :8705-8708

[2] Humanized monoclonal anti-CD25 antibody as a novel therapeutic option in HIV-associated psoriatic erythroderma [J].

Dichmann, S ;

Mrowietz, U ;

Schöpf, E ;

Norgauer, J .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 47 (04) :635-636

[3]

KAUFMAN MD, 2007, 60 AM AC NEUR M AAN

[4] Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis [J].

Krueger, JG ;

Walters, IB ;

Miyazawa, M ;

Gilleaudeau, P ;

Hakimi, J ;

Light, S ;

Sherr, A ;

Gottlieb, AB .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 43 (03) :448-458

[5] Daclizumab phase II trial in relapsing and remitting multiple sclerosis - MRI and clinical results [J].

Rose, J. W. ;

Burns, J. B. ;

Bjorklund, J. ;

Klein, J. ;

Watt, H. E. ;

Carlson, G. .

NEUROLOGY, 2007, 69 (08) :785-789

[6] Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody [J].

Rose, JW ;

Watt, HE ;

White, AT ;

Carlson, NG .

ANNALS OF NEUROLOGY, 2004, 56 (06) :864-867

[7] A 31-year-old woman with rash, fever, and hypotension - Acute necrotizing eosinophilic myocarditis associated with a systemic necrotizing inflammatory process also involving skeletal muscle, the liver, and the spinal cord, most consistent with a severe drug-induced hypersensitivity reaction. [J].

Sabatine, Marc S. ;

Poh, Kian-Keong ;

Mega, Jessica L. ;

Shepard, Jo-Anne O. ;

Stone, James R. ;

Frosch, Matthew P. ;

Greenberg, Jeffrey O. ;

Baggish, Aaron .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2167-2178

[8] Treatment of recalcitrant psoriasis with daclizumab [J].

Wohlrab, J ;

Fischer, M ;

Taube, KM ;

Marsch, WC .

BRITISH JOURNAL OF DERMATOLOGY, 2001, 144 (01) :209-210

← 1 →